Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COM503 Alone or With Zimberelimab in Advanced Solid Tumors
NCT06759649Phase 1Recruiting
- Sponsor
- Compugen Ltd.
- Start
- Jan 2025
- Primary completion
- Nov 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of COM503 in solid tumor (5 arms), sponsored by Compugen Ltd. Primary endpoints: Safety profile of COM503 as monotherapy at 90 days and Safety profile of COM503 in combination with zimberelimab at 90 days. Started Jan 2025; status: recruiting.
02
Drugs
COM503
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06759649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06759649.